This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:diseases:celiac [02.19.2019] – [recent research] sallieq | home:diseases:celiac [07.12.2019] – [recent research] sallieq | ||
---|---|---|---|
Line 63: | Line 63: | ||
[[http:// | [[http:// | ||
(({{pubmed> | (({{pubmed> | ||
+ | |||
+ | Findings suggest that neither olmesartan nor other ARBs were associated with diarrhea among patients undergoing endoscopy. The spruelike enteropathy recently associated with olmesartan is likely a rare adverse effect and milder presentations are unlikely. | ||
+ | |||
+ | 2018 data show that OLM is an Nrf2 activator, NFkB inhibitor and apoptosis inhibitor in an experimental model of ulcerative colitis. Overall, the study indicates that OLM shows promise as a potential therapy for the treatment of human inflammatory bowel diseases. | ||
+ | (({{pubmed> | ||
{{tag> | {{tag> |